All In Biotech

Drug Trial Radar · NCT06272747

Study of XH-S003 in Healthy Volunteers

A Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of XH-S003 After Single Ascending Doses, Multiple Ascending Doses and Evaluation of Food Effects in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Jul 10, 2023

Primary completion

Jul 30, 2024

Study completion Nov 30, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.

Conditions

  • Healthy Adults

Interventions

  • XH-S003Drug

    IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

  • PlaceboDrug

    Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Part A: Approximately 1~2 weeks
  2. Number of participants with adverse events (AEs)Time frame: Part B: Approximately 3~4weeks
  3. Number of participants with adverse events (AEs)Time frame: Part C: Approximately 3~4weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Friendship Hospital,Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.